🇺🇸 FDA
Patent

US 10517860

Combination of pimavanserin and cytochrome P450 modulators

granted A61KA61K31/4468A61K31/496

Quick answer

US patent 10517860 (Combination of pimavanserin and cytochrome P450 modulators) held by ACADIA Pharmaceuticals Inc. expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ACADIA Pharmaceuticals Inc.
Grant date
Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/4468, A61K31/496, A61K31/7048, A61K45/06